MADRIGAL PHARMACEUTICALS, INC.: 10-Q/A filed 2017-03-31
What MADRIGAL PHARMACEUTICALS, INC. reported in its quarterly report amendment filed 2017-03-31 (fiscal Q3 2016): 20 published measures, 48 facts as tagged in accession 0001104659-17-020706.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-Q/A (quarterly report amendment)
- Filed
- 2017-03-31
- Fiscal period
- fiscal Q3 2016
- Accession
- 0001104659-17-020706 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MADRIGAL PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 41,507,184 | USD | |
| At 2015-12-31 | 363,581 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 3,915,390 | USD | |
| At 2015-12-31 | 49,276,940 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 37,591,794 | USD | |
| At 2015-12-31 | -48,913,359 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 8,393,302 | USD | |
| At 2015-12-31 | 306,249 | USD | |
| At 2015-09-30 | 52,557 | USD | |
| At 2014-12-31 | 148,066 | USD |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 1,476 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | -67,558,179 | USD | |
| At 2015-12-31 | -48,919,590 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,476 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-09-30 | 8,102,939 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -14,090,518 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -17,467,847 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -880,029 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -2,314,564 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 41,190,638 | USD | |
| At 2015-12-31 | 363,581 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 3,915,390 | USD | |
| At 2015-12-31 | 49,276,940 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,159,836 | USD | |
| At 2015-12-31 | 102,293 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 14,090,518 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 17,467,847 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 880,029 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 2,314,564 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 11,570,149 | shares | |
| At 2015-12-31 | 176,158 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | -12,485 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 2,755,554 | USD | |
| At 2015-12-31 | 70,203 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-09-30 | 1,632,783 | USD | |
| At 2015-12-31 | 50,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -14,061,225 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -18,651,074 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -1,799,834 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -4,962,094 | USD | 273 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | -14,048,740 | USD | 92 |
| 2016-01-01 to 2016-09-30 | -18,638,589 | USD | 274 |
| 2015-07-01 to 2015-09-30 | -1,799,834 | USD | 92 |
| 2015-01-01 to 2015-09-30 | -4,962,094 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-09-30 | 6,285,597 | USD | 92 |
| 2016-01-01 to 2016-09-30 | 7,058,345 | USD | 274 |
| 2015-07-01 to 2015-09-30 | 197,441 | USD | 92 |
| 2015-01-01 to 2015-09-30 | 660,642 | USD | 273 |
Inspect the source
- Entity
- MADRIGAL PHARMACEUTICALS, INC. / CIK 0001157601
- Captured
- 2026-09-20T07:42:41.125Z
- SEC response SHA-256
0d1b2363eed5fd0a7c9252ccbad177dd16230bd15986785daf99c7a8d23f207e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001157601.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))